Recruiting

Observational Study

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06409052

Conditions

Endometrial Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Qualitative interviews

Study Details

Brief summary:

To learn more about women's attitudes toward and knowledge about endometrial cancer and options that might decrease the risk of developing

Conditions

Endometrial Cancer

Study ID

NCT06409052

Start date

Jun 25, 2024

Status verified date

Jul, 2026

Completion date

Aug 3, 2026

Anticipated

Primary completion date

Aug 3, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Women who present to MD Anderson Cancer Center including MDA Houston Area Locations with a diagnosis of endometrial cancer
2. Women who present to MD Anderson Cancer Center including MDA Houston Area Locations with a diagnosis of abnormal uterine bleeding or endometrial hyperplasia
3. Women without a diagnosis of endometrial cancer or endometrial hyperplasia
4. Women must be at least 18 years or age
5. Women must be able to read, write, and speak English
6. Women must be willing and able to provide written informed consent

Exclusion Criteria:

Study Design

Enrollment

45 participants

Anticipated

Interventions and Outcome Measures

Interventions

Qualitative interviews

Interviews will be conducted for approximately 45-60 minutes

Primary outcome measure

  • Patient education [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts and Locations

Central contacts

Larissa Meyer, MD

(713) 745-0973lmeyer@mdanderson.org

Locations

MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Larissa Meyer Meyer, MD

713-745-0973lmeyer@mdanderson.org

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Jul 16, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-07-16.